FDCC
CRSP icon

Foster Dykema Cabot & Co’s CRISPR Therapeutics CRSP Stock Holding History

Foster Dykema Cabot & Co’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$0 Hold
10
– – ﹤0.01% 342
2023
Q2 		$1K Hold
10
– – ﹤0.01% 366
2023
Q1 		$0 Buy
+10
New +$486 ﹤0.01% 240

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Foster Dykema Cabot & Co's CRSP Position: Q3 2023 in Review

Foster Dykema Cabot & Co held its CRISPR Therapeutics (CRSP) position steady in Q3 2023 at 10 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #342.

Foster Dykema Cabot & Co first reported a position in CRSP in Q1 2023 and has held it in 3 quarters since. The position peaked at $1K in Q2 2023. 406 funds tracked by Wall St. Rank hold CRSP as of Q3 2023.

  • Foster Dykema Cabot & Co held 10 shares of CRISPR Therapeutics worth $0 as of Q3 2023.
  • Foster Dykema Cabot & Co left its CRISPR Therapeutics share count unchanged in Q3 2023.
  • CRISPR Therapeutics made up ﹤0.01% of Foster Dykema Cabot & Co's portfolio in Q3 2023, its #342 holding.
  • Foster Dykema Cabot & Co first reported a position in CRISPR Therapeutics in Q1 2023 and has held it in 3 quarters since.
  • Foster Dykema Cabot & Co's CRISPR Therapeutics position peaked at $1K in Q2 2023.
  • 406 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2023.

Based on Foster Dykema Cabot & Co's 13F filing for Q3 2023, filed 14 Nov 2023.